K Pharma (4896) · RiskRestated
Dependence on Founders and Key Researchers
First written in FY2023. 2 of 3 entries say "Restated". Latest entry: FY2025.
3entries
3years
0from disclosures
How it moved
Same theme, other companies
Dependence on key executivesA theme 560 companies write about · 560 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2026: 10 of 77 companies on the "Worse" side.
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 560 threads.Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「We believe that our research and development activities and business development depend heavily on both individuals.」
The company reiterates its dependence on the research results, joint research and management involvement of Hideyuki Okano and Masaya Nakamura. - FY2024RestatedAnnual report
「We believe that our research and development activities and business development depend heavily on both individuals.」
The company reiterates its dependence on the research results, joint research and management involvement of Hideyuki Okano and Masaya Nakamura. - FY2023First statedAnnual report
「We believe that our research and development activities and business development depend heavily on both individuals.」
The company describes its dependence on the research results, joint research and management involvement of Hideyuki Okano and Masaya Nakamura as a risk.